Short answer
Dyne Therapeutics, Inc. (DYN) filed an 8-K current report with the SEC on November 5, 2026 reporting Item 2.02 (Results of Operations and Financial Condition), Item EX-99.1 (Exhibit EX-99.1). Q3 2026 financial results announced for quarter ended September 30, 2026.
Dyne Therapeutics, Inc. 8-K event analysis
AI summary of each reported item and its exhibits
Item 2.02 · Results of Operations and Financial Condition
- Q3 2026 financial results announced for quarter ended September 30, 2026
- Full results and management commentary available in Exhibit 99.1 press release
Item EX-99.1 · Exhibit EX-99.1
- FDA priority review for z-rostudirsen, with PDUFA action date January 21, 2027, creates the near-term approval catalyst
- Cash, cash equivalents and marketable securities of $1.134 billion expected to fund operations into Q2 2028
- Q3 R&D expenses rose to $161.7 million from $97.2 million, reflecting manufacturing and Phase 3 trial investment
- Net loss widened to $193.6 million, or $1.06 per share, from $108.0 million, or $0.76 per share
- ACHIEVE topline data planned for Q1 2027, supporting a potential z-basivarsen BLA submission in Q3 2027
Generated from the filing text and exhibits; verify against the original. What 8-K item codes mean
Other Dyne Therapeutics, Inc. 8-K filings
Get the next DYN 8-K as it lands
Follow DYN for push alerts, or ask the research agent what this filing means.